VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 – Minichart
VivoSim Labs (Nasdaq: VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) by meeting the $2.5M stockholders’ equity requirement. The company reported cash of about $10.1M as of Aug. 3, 2026, after receiving $5M from Eli Lilly and $1M from escrow, and completing a July 17 financing raising $4M gross. It reiterated guidance for 2027 revenue growth of 500%+.
How this was made
The 30-second read
Why it matters
Restoring Nasdaq compliance reduces delisting risk, while the July warrant financing and FXR-program-related cash inflows improve near-term liquidity. The reiterated 2027 revenue growth target may attract growth-oriented flows, but dilution from warrant exercises is a key counterweight.
Market read
This is a microcap balance-sheet and listing-compliance reset: restored Nasdaq compliance plus $10.1M cash and a $4M gross warrant financing can materially change perceived survival risk and near-term trading dynamics.
What to watch
The article notes these cash/financing items are not reflected in the latest audited financials and are subject to adjustment, so traders should verify the corresponding SEC filings and final accounting treatment before extrapolating.
Background
VivoSim Labs is a preclinical drug safety services provider using NAM 3D cellular models, and it had been at risk under Nasdaq’s minimum stockholders’ equity rule.
Ticker impact
VivoSim says it regained Nasdaq equity compliance, raised about $3.6M net via a July 17 warrant financing, and reports $10.1M cash as of Aug 3.
Likely positive near-term bias as traders price reduced delisting risk and improved liquidity, though dilution risk from warrant exercises can cap upside.
The article provides multiple concrete, time-stamped balance-sheet and listing-compliance updates (equity threshold, cash on hand, financing terms, warrant exercise share count) plus reiterated revenue guidance, which together can move microcap sentiment and liquidity expectations.
Market effects
Supports sentiment for NAM/3D cellular model CROs by highlighting liquidity stabilization and continued contract-research momentum narrative.
Limited, primarily affects US microcap biotech services sentiment rather than broader regional fundamentals.
Low; the disclosed counterparty is Eli Lilly, but the update is company-specific and not a cross-market macro shock.
Counterpoint
The warrant-driven share expansion (from ~3.19M to ~13.39M shares) may imply ongoing dilution, so the cash boost could be partially offset by future dilution and financing dependence.
Key entities
- companyVivoSim Labs, Inc.
Nasdaq-listed NAM 3D cellular model provider that regained Nasdaq equity compliance and reported cash/financing updates.
- companyEli Lilly and Company
Counterparty referenced for a $5M milestone payment and $1M escrow release tied to VivoSim’s FXR program sale.
- regulationNasdaq Listing Rule 5550(b)(1)
Minimum stockholders’ equity requirement VivoSim says it has met to restore compliance.
